GlassScriptPhysician profile
Maribel Rey
NPI 1790549178
$3,618.27
in general payments reported to CMS, 2019-2025
19 companies · $1,982 in 2025
The $1,982 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $12.88 · 2024: $1,623 · 2025: $1,982.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,518.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $506.95 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $503.72 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $404.80 | 2024-2025 | Cobenfy |
| Abbvie INC. | $349.75 | 2024-2025 | |
| Axsome Therapeutics, INC. | $284.44 | 2024-2025 | Auvelity |
| Alkermes, INC. | $243.91 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $217.88 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $205.04 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $198.31 | 2024-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $183.87 | 2024-2025 | Ingrezza |
| Indivior INC. | $142.53 | 2025 | Sublocade |
| Corium, LLC | $96.59 | 2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $83.63 | 2024 | Trintellix |
| Lundbeck LLC | $76.56 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $31.62 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $30.38 | 2024 | |
| Idorsia Pharmaceuticals US INC | $28.30 | 2024 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.29 | 2024 | |
| Neos Therapeutics, LP | $13.70 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribel Rey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.